iQ&A Interactive Cardiovascular Intelligence Zone for Stroke Prevention in Atrial Fibrillation (SPAF)
The Interactive Medical Intelligence Zone is a needs assessment-driven continuing medical education (CME) activity that utilizes national and international experts to provide evidence-based, guideline-consistent, and practice behavior-changing information focused on critical and challenging topics in clinical medicine.
To ensure that the educational content of iQ&A programs will address practice gaps in clinical medicine, improve patient outcomes, and positively guide clinical practice strategies, international experts, usually in a roundtable format, will respond to questions submitted and/or generated by practitioners at CME mega-symposia, national congress, association meetings, or as part of on-line, enduring CME programs.
Questions reflecting the clinical needs of practitioners are then answered, analyzed, and discussed by international experts, who provide evidence-based and clinically relevant guidance that is independently of commercial sources or the program sponsor.
The iQ&A platform stresses:
  • Needs assessment-driven CME content
  • Evidence-based analysis
  • Expert-based guidance and consultation
  • Compliance adherence
  • Independence of content generation
  • Landmark trials
  • Association-generated practice management guidelines
  • Quality of care improvement
  • Practice gap improvement

Program Medium
Internet-based program

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period October 9, 2013 through October 9, 2015, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 157 segments, totaling 6.5 hours, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in the management of stroke prevention in the setting of atrial fibrillation.

Release Date

October 9, 2013

Expiration Date

October 9, 2015

Intended Audience

This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with familial hypercholesterolemia.

This constituency of HCPs shall include the following audience:

  • Cardiologists
  • Thrombosis medicine specialists
  • Neurologists
  • Preventive medicine specialists
  • Cardiology department program directors
  • Clinical geneticists
  • Clinical cardiovascular pharmacists
  • Related specialists


Participation in this iQ&A interactive Medical Intelligence Zone for SPAF is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

Supported by an educational grant from Boehringer Ingelheim.

Boehringer Ingelheim

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School Office of Continuing Medical Education (UMMS-OCME) and CMEducation Resources, LLC. The UMMS-OCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates his enduring material for a maximum of 6.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

Samuel Z. Goldhaber, MD
Program Chairman and Moderator
Professor of Medicine
Harvard Medical School
Director, VTE Research Group
Cardiovascular Division
Brigham and Women's Hospital
President, North American Thrombosis Forum (NATF)
Boston, Massachusetts

Consultant: Baxter, Boehringer Ingelheim, Bristol Myers Squibb,
Daiichi Sankyo, Eisai, Merck, Pfizer, Portola, Sanofi Aventis
Research Support: Daiichi Sankyo, Eisai, EKOS, J&J, Sanofi Aventis


John Amerena, MD
Geelong Cardiology Research Centre
Deakin University
Victoria, Australia

Nothing to disclose

Dan Atar, MD, PhD
Department of Cardiology
Oslo University Hospital Ullevaal
Oslo, Norway

Speaker and Consultant: BMS/Pfizer, Bayer, Boehringer-Ingelheim, Merck, sanofi-aventis


Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI
Chief of Cardiology, VA Boston Healthcare System
Director, Integrated Interventional Cardiovascular
Program, Brigham and Women’s Hospital and the
VA Boston Healthcare System
Senior Investigator, TIMI Group
Harvard Medical School
Boston, Massachusetts

Consultant: Arena, Astra Zeneca, Bristol-Myers Squibb, Cardax, Cogentus, Daiichi Sankyo, Eli Lilly, Eisai, Glaxo Smith Kline, Johnson & Johnson, Medtronic, Millennium, Otsuka, Paringenix, PDL, Philips, Portola, sanofi-aventis, Schering Plough, Takeda, The Medicines Company, Vertex.
Principal Investigator for several potentially related studies. His institution has received funding from Bristol Myers Squibb, Eisai, Ethicon, Heartscape, sanofi-aventis, The Medicines Company


Paolo Colonna, MD
Cardiology Department General Hospital
Institute of Cardiology
Policlinico of Bari
Bari, Italy

Nothing to disclose


Raffaele De Caterina, MD, PhD
Professor of Cardiology
Chairman of Cardiology and Director,
  Postgraduate School of Cardiology
‘G d’Annunzio’ University in Chieti
Chiete, Italy

Consultant and speaker fees: AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and Lilly
Grants/Research Support: AstraZeneca and Boehringer-Ingelheim

John W. Eikelboom, MD
Associate Professor of Medicine
McMaster University
Canada Research Chair in Cardiovascular Medicine
Ontario, Canada

Speaker: AstraZeneca, Boehringer Ingelheim, and sanofi-aventis.


Andreas Goette, MD
Professor of Medicine
Chairman of Cardiology
St. Vincent Hospital Paderborn
Paderborn, Germany

Consultant: Merck & Co., Inc.; sanofi-aventis
Speaker: Merck & Co., Inc.; sanofi-aventis


Bulent Gorenek, MD
Eskisehir Osmangazi University
Cardiology Department
Eskisehir, Turkey

Nothing to disclose


Christopher B. Granger, MD
Professor of Medicine
Cardiac Care Unit; Co-Director
Cardiovascular Clinical Trials
Duke University Medical Center
Durham, North Carolina

Advisor or Consultant: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co., Ltd.; sanofi-aventis; The Medicines Company
Grants/Research Support: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; Eli Lilly and Company; Medtronic, Inc.; Merck & Co., Inc.; sanofi-aventis; The Medicines Company


Stefan H. Hohnloser, MD
Director, Department of Clinical Electrophysiology
J. W. Goethe University
Frankfurt, Germany

Consultant: sanofi-aventis, Boehringer Ingelheim, St. Jude Medical, Cardiome Pharma Corp., ARYx Therapeutics, Bristol-Myers Squibb
Speaker/Speaker’s Bureau: sanofi-aventis, Boehringer Ingelheim, St. Jude Medical, Cardiome Pharma Corp., ARYx Therapeutics, Bristol-Myers Squibb
Grant/Research Support: sanofi-aventis, St. Jude Medical


Ajay Kakkar, MBBS, PhD, FRCS
Head of the Centre for Surgical Sciences
Barts and the London
Queen Mary's School of Medicine and Dentistry
Thrombosis Research Institute
London, UK

Consultant: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Eisai Co., Ltd.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Sanofi
Grant/Research Support: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Eisai Co., Ltd.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Sanofi


Philippe Kolh, MD, PhD
Professor of Physiology
University of Liège
 Liège, Belgium

Consultant: AstraZeneca Pharmaceuticals LP; Merck & Co., Inc.
Speaker: AstraZeneca Pharmaceuticals LP


Gregory Y.H. Lip, MD, FRCP, FACC, FESC
Consultant Cardiologist and Professor of Cardiovascular Medicine
Director, Haemostasis Thrombosis & Vascular Biology Unit
University of Birmingham Centre for Cardiovascular Sciences
City Hospital
Birmingham, England

Advisor or consultant: Boehringer Ingelheim Pharmaceuticals, Inc.; sanofi-aventis; Bayer HealthCare Pharmaceuticals; Merck & Co., Inc.; Astellas Pharma, Inc.; Portola Pharmaceuticals, Inc.; BIOTRONIK, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Pfizer Inc 
Speaker or a member of a speakers bureau: Boehringer Ingelheim Pharmaceuticals, Inc.; sanofi-aventis; Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb Company; Pfizer Inc.


Jean-Yves F. Le Heuzey, MD
Professor of Cardiology
Head, Arrhythmia Department
Hôpital Européen Georges Pompidou
Paris, France

Research support/advisory boards: sanofi-aventis, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Pfizer, Daiichi Sankyo


Renato D. Lopes, MD, PhD
Adjunct Professor of Medicine
Duke University Medical Center
Durham, NC
Federal University of São Paulo
Executive Director
Brazilian Clinical Research Institute
São Paulo, Brazil

Advisor or consultant: Boehringer Ingelheim Pharmaceuticals, Inc. Received grants for clinical research from: Bristol-Myers Squibb Company

Leopoldo Piegas, MD, PhD, FACC
Clinical Division Director
Instituto Dante Pazzanese de Cardiologia
São Paulo, Brazil

Nothing to disclose


Tatjana S. Potpara, MD, PhD, FESC
Department of Cardiology
Institute for Cardiovascular Diseases
Clinical Center of Serbia
Medical Faculty, Belgrade University
Belgrade, Serbia

Advisory Board: Boehringer-Ingelheim

Christian T. Ruff, MD, MPH
Associate Physician Cardiovascular Division
Brigham and Women’s Hospital
Instructor of Medicine
Harvard Medical School
Boston, MA

Advisory Board: Daiichi Sankyo and Boehringer Ingelheim


Alexander G. G. Turpie, MD, FRCP, FACP, FACC, FRCPC
Professor of Medicine, Emeritus
Department of Medicine
Hamilton Health Sciences-General Hospital
Hamilton, Ontario

Consultant: Bayer Pharma, Janssen, Astellas, Takeda
Speaker’s Bureau: Janssen, Boehringer-Ingelheim


Isabelle C. Van Gelder, MD, PhD
Department of Cardiology
Thoraxcenter, University Medical Center Groningen
University of Groningen
Groningen, The Netherlands

Consultant:  Medtronic, MSD, Sanofi-Aventis, and Boehringer Ingelheim;
Grant/Research Support: Astra Zeneca,Biotronik, Medtronic, Sanofi-Aventis, Boehringer Ingelheim, St Jude Medical, and Boston Scientific

Freek Verheugt, MD, PhD
Professor of Cardiology
Onze Lieve Vrouwe Gasthuis
Amsterdam, Netherlands

Consultant: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb Company
 Speaker: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb Company

Jeffrey I. Weitz, MD FRCP, FACP
Professor of Medicine and Biochemistry
McMaster University
Canada Research Chair in Thrombosis
Heart and Stroke Foundation
J.F. Mustard Chair in Cardiovascular Research
Hamilton, Ontario

Advisor or consultant: Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; sanofi-aventis; Daiichi Sankyo, Inc.; Takeda Pharmaceuticals North America, Inc.; Bayer HealthCare Pharmaceuticals; Pfizer Inc.; Portola Pharmaceuticals, Inc.; Merck & Co., Inc.


Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.
Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Understand advances in oral anticoagulation based on new mechanisms involving inhibition of targeted factors in the coagulation cascade; and the possible implications of these advances for prophylaxis of arterial thromboembolism and stroke in the setting of atrial fibrillation;
  • Implement the ESC 2012 AF Practice Statement/Guidelines for SPAF, and understand the role of NOACs in the clinical decision tree for SPAF, and the risk-directed indications for their deployment in patients with AF;
  • Apply the evidence and data from landmark SPAF trials, and understand the clinical implications of these trials, including evolving subset analysis, long-duration post-study outcomes;
  • Apply findings, conclusions, and guidance generated and reported by regulatory bodies in Europe, Australia, U.S. and other countries (i.e., from EMA as well as FDA and other agencies) and better understand their analysis of bleeding rates with NOACs observed in the clinical trials vs. those observed in post-marketing, real world experience;
  • Detail the consequences and bleeding outcomes in warfarin-treated patients who experience bleeding vs. bleeding outcomes in patients who are managed with NOAC
Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.


Copyright © 2013 by CMEducation Resources, LLC All rights reserved. 

Reproduction, distribution, or translation without express written permission is strictly prohibited. 

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity. 

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations. 

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman. 

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
Copyright © CMEducation Resources, LLC